AMPH Q2 2019 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q2 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$79M+11.3% YoY

Gross Profit

$32M41.0% margin

Operating Income

$973,0001.2% margin

Net Income

$48M60.5% margin

EPS (Diluted)

$0.96

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$52M

Free Cash Flow

$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$601M

Total Liabilities

$169M

Stockholders' Equity

$388M

Cash & Equivalents

$120M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$79M	$71M	+11.3%
Gross Profit	$32M	$26M	+23.8%
Operating Income	$973,000	-$3M	+134.1%
Net Income	$48M	-$3M	+1812.8%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$5M100%

Geographic Segments

U

$75M99%

C

$984,0001%